HER3 inhibitor

DRUG CLASS:

HER3 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	MM-121 Sensitive: B - Late Trials MM-121 Sensitive : B	MM-121 Sensitive: B - Late Trials MM-121 Sensitive : B
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Non Small Cell Lung Cancer	NRG1 fusion	Non Small Cell Lung Cancer	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Pancreatic Ductal Adenocarcinoma	NRG1 fusion	Pancreatic Ductal Adenocarcinoma	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B	zenocutuzumab-zbco Sensitive: B - Late Trials zenocutuzumab-zbco Sensitive : B
NRG1 fusion	Lung Cancer	NRG1 fusion	Lung Cancer	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2
NRG1 fusion	Ovarian Cancer	NRG1 fusion	Ovarian Cancer	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2
NRG1 fusion	Cholangiocarcinoma	NRG1 fusion	Cholangiocarcinoma	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2
NRG1 fusion	Breast Cancer	NRG1 fusion	Breast Cancer	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2	zenocutuzumab-zbco Sensitive: C2 – Inclusion Criteria zenocutuzumab-zbco Sensitive : C2
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	SI-B001 Sensitive: C2 – Inclusion Criteria SI-B001 Sensitive : C2	SI-B001 Sensitive: C2 – Inclusion Criteria SI-B001 Sensitive : C2
NRG1 overexpression	Esophageal Squamous Cell Carcinoma	NRG1 overexpression	Esophageal Squamous Cell Carcinoma	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3	AV-203 Sensitive: C3 – Early Trials AV-203 Sensitive : C3
EGFR mutation	Squamous Cell Carcinoma of Head and Neck	EGFR mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
NRG1 mutation	Squamous Cell Carcinoma of Head and Neck	NRG1 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
HER-2 mutation	Squamous Cell Carcinoma of Head and Neck	HER-2 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3
ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck	ERBB3 mutation	Squamous Cell Carcinoma of Head and Neck	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3	cetuximab + ISU104 Sensitive: C3 – Early Trials cetuximab + ISU104 Sensitive : C3
NRG1 overexpression	Non Small Cell Lung Cancer	NRG1 overexpression	Non Small Cell Lung Cancer	U3-1287 Sensitive: C3 – Early Trials U3-1287 Sensitive : C3	U3-1287 Sensitive: C3 – Early Trials U3-1287 Sensitive : C3
ATP1B1-NRG1 fusion	Pancreatic Cancer	ATP1B1-NRG1 fusion	Pancreatic Cancer	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3	zenocutuzumab-zbco Sensitive: C3 – Early Trials zenocutuzumab-zbco Sensitive : C3
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials trastuzumab + alpelisib + LJM-716 Sensitive : C3	trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials trastuzumab + alpelisib + LJM-716 Sensitive : C3
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab + zenocutuzumab-zbco Sensitive: C3 – Early Trials trastuzumab + zenocutuzumab-zbco Sensitive : C3	trastuzumab + zenocutuzumab-zbco Sensitive: C3 – Early Trials trastuzumab + zenocutuzumab-zbco Sensitive : C3
CD74-NRG1 fusion	Non Small Cell Lung Cancer	CD74-NRG1 fusion	Non Small Cell Lung Cancer	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4
SLC3A2-NRG1 fusion	Estrogen Receptor Positive Breast Cancer	SLC3A2-NRG1 fusion	Estrogen Receptor Positive Breast Cancer	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4	zenocutuzumab-zbco Sensitive: C4 – Case Studies zenocutuzumab-zbco Sensitive : C4
CLU-NRG1 fusion	Ovarian Cancer	CLU-NRG1 fusion	Ovarian Cancer	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D
SLC3A2-NRG1 fusion	Pancreatic Ductal Adenocarcinoma	SLC3A2-NRG1 fusion	Pancreatic Ductal Adenocarcinoma	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D
ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma	ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D
CLU-NRG1 fusion	Ovarian Cancer	CLU-NRG1 fusion	Ovarian Cancer	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D
SLC3A2-NRG1 fusion	Ovarian Cancer	SLC3A2-NRG1 fusion	Ovarian Cancer	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D	zenocutuzumab-zbco Sensitive: D – Preclinical zenocutuzumab-zbco Sensitive : D
CD74-NRG1 fusion	Lung Cancer	CD74-NRG1 fusion	Lung Cancer	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D
SLC3A2-NRG1 fusion	Lung Cancer	SLC3A2-NRG1 fusion	Lung Cancer	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D	MM-121 Sensitive: D – Preclinical MM-121 Sensitive : D

HER3 inhibitor

HER3 inhibitor

Associations(40)

Associations
(40)